Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 03:59:48 2024-06-04 pm EDT 5-day change 1st Jan Change
145.4 USD -1.64% Intraday chart for Moderna, Inc. -5.10% +46.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Moderna, Inc. - Special Call
Sector Update: Health Care Stocks Edge Higher Monday Afternoon MT
RBC Raises Moderna's PT to $160 From $135 Amid RSV Vaccine Approval From US FDA, Keeps Outperform Rating MT
Moderna: successful melanoma trial with Merck CF
Merck, Moderna Drug Combo Shows Improved Survival in Skin Cancer Trial DJ
A rate cut is finally in sight Our Logo
Moderna, Merck Say 3-Year Data for Melanoma Combination Therapy Show Continued Improvement in Recurrence-Free Survival MT
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says RE
Moderna & Merck Announces 3-Year Data for mRNA-4157 in Combination with KEYTRUDA (Pembrolizumab) CI
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up RE
RBC Raises Price Target on Moderna to $160 From $135 Amid RSV Vaccine Approval From FDA, Keeps Outperform Rating MT
MODERNA : Oddo BHF raises its target price on the stock CF
ANALYSTS RECOMMENDATIONS : Best Buy, Dell Technologies, Moderna, AMD, National Grid... Our Logo
Moderna Insider Sold Shares Worth $2,901,585, According to a Recent SEC Filing MT
Health Care Stocks Climb On Drug News -- Health Care Roundup DJ
Equities Mostly Rise as Fed's Preferred Inflation Measure Meets Street Views MT
Equities Mostly Rise as Fed's Preferred Inflation Measure Meets Expectations MT
RBC Raises Moderna's Price Target to $160 From $135 MT
Moderna Gets FDA Approval For Respiratory Syncytial Virus Vaccine for Seniors MT
Top Midday Stories: SQM, Codelco to Mine Lithium; Moderna Gets Approval for RSV Vaccine; Tesla Recalls Over 100,000 Cars; Icahn Amasses Stake in Caesars MT
Moderna Secures FDA Approval for mRESVIA Vaccine MT
Moderna Gets FDA Approval For RSV Vaccine MT
Moderna Gets FDA Approval For RSV Vaccine mRESVIA MT
US FDA approves Moderna's RSV vaccine, its second marketed product RE
Transcript : Moderna, Inc. Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-31-2024 10:00 AM
Chart Moderna, Inc.
More charts
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
147.8 USD
Average target price
142.8 USD
Spread / Average Target
-3.39%
Consensus
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. News Moderna, Inc.
  5. Moderna's RSV Vaccine Review Delayed by FDA to End of May